Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIIB054 (Cinpanemab) Safety and PK in Japanese PD Patients
NCT03716570Phase 1Terminated
- Sponsor
- Biogen
- Start
- Mar 2019
- Primary completion
- Apr 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cinpanemab in Parkinson's disease (PD) (4 arms), sponsored by Biogen. Primary endpoint: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) up to 72 Weeks. Started Mar 2019; status: terminated.
02
Drugs
cinpanemab
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03716570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03716570.